NKGen Biotech (NKGN) has issued an update.
NKGen Biotech, Inc. has announced the appointment of Dr. Marco Gottardis as a Class I director, filling the vacancy left by Ms. Alana McNulty’s resignation. Dr. Gottardis, with a distinguished background in biopharmaceuticals, including leadership roles at Janssen Pharmaceuticals and consulting at Gottardis Biotech LLC, was also chosen to serve on the Audit, Compensation, and N&CG Committees. His appointment is accompanied by a compensation program and a stock option award, with no reported conflicts of interest or related party transactions.
Learn more about NKGN stock on TipRanks’ Stock Analysis page.
